Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Briefs: Medtronic’s New Renal Denervation Trial; CPAP Combats Hypertension; Prosigna Breast Cancer Assay

This article was originally published in The Gray Sheet

Executive Summary

Medtronic launches the SYMPLICITY HTN-4 trial in moderate hypertension patients. Trial shows CPAP for sleep-apnea patients can also improve blood pressure. The information provided by NanoString’s breast cancer assay could help patients avoid unnecessary chemotherapy.

You may also be interested in...



St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment

Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.

Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date

The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.

Obstructive Sleep Apnea: CPAP Under Pressure As New Market Segments Awaken

An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT032704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel